Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Peacefulwendy, $Pistol Pete$, thenewmixer, fraum, concordia
Search This Board: 
Last Post: 12/13/2017 1:28:45 AM - Followers: 786 - Board type: Free - Posts Today: 1

Welcome to PharmaCyte BioTech
An OTCQB Company

PharmaCyte is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. For cancer, the therapy involves encapsulating genetically engineered human cells that convert the prodrug ifosfamide from its inactive form to its "cancer" killing form. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then ifosfamide is given IV at one-third the normal dose. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver (where ifosfamide is normally activated) and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a "bio-artificial pancreas" for purposes of insulin production.



FDA Grants Orphan Drug Designation to Pharmacyte Biotech for Pancreatic Cancer Treatment

European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation to PharmaCyte’s subsidiary,
PharmaCyte Biotech Europe Limited, for PharmaCyte’s pancreatic cancer treatment

 Company Address
PharmaCyte Biotech, Inc.

23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92652
Office Number: 917.595.2850
Facsimile Number: 917.595.2851

Market Value:
$122,386,272 a/o Dec 19, 2016

Shares Outstanding:
848,904,665 a/o Aug 29, 2016

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

817,204,665 a/o Aug 29, 2016

For more updated information please visit:

Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations

Stonegate Capital Inc.
8201 Preston Road
Suite 325
Dallas, TX 75225
United States


   All News Releases:


What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans. 

Management Team:

Kenneth L. Waggoner, Chief Executive Officer and President

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director

Carlos A. Trujillo – Chief Financial Officer and Director

Walter H. Gunzburg – Chief Scientific Officer

Dr. Matthias Lohr as Chairman of Scientific Advisory Board

Thomas Liquard - Chairman of the Audit Committe

  Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development

Dr. Manuel Hidalgo, Scientific Advisory Board





-  The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
-  We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
-  There are no guarantees when buying or selling any security.



Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PMCB News: Current Report Filing (8-k) 10/10/2017 08:31:01 AM
PMCB News: Notice of Effectiveness (effect) 09/29/2017 06:01:57 AM
PMCB News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 09/28/2017 04:18:18 PM
PMCB News: Securities Registration Statement (simplified Form) (s-3) 09/13/2017 09:26:54 AM
PMCB News: Quarterly Report (10-q) 09/13/2017 06:06:08 AM
#79107  Sticky Note $PMCB PharmaCyte Biotech Meets with Oncology Advisory Bo $Pistol Pete$ 12/12/17 02:13:03 AM
#78845  Sticky Note Daily SCAM ALERT. Below are the headlines of concordia 11/30/17 11:31:41 AM
#62231  Sticky Note in full/ #2/ 01-28-2017/ Keeping an Eye on mick 01/28/17 07:35:33 PM
#52881  Sticky Note Here is a very nice list of accomplishments... Peacefulwendy 09/28/16 11:17:44 AM
#79120   Hope PMCB pps can be like BitCoin one day. WallSt1 12/13/17 01:28:44 AM
#79119   You’re still here so I’m still here. BioInvestor4 12/12/17 10:44:51 PM
#79118   $PMCB Daily and Weekly Charts http://www.stock $Pistol Pete$ 12/12/17 09:22:12 PM
#79117   No volume = no interest in the scam frosr6 12/12/17 09:20:19 PM
#79116   $PMCB strong hold today and lots of resistance $Pistol Pete$ 12/12/17 08:22:43 PM
#79115   Going out on a limb here... PINKribbon 12/12/17 07:36:04 PM
#79114   Pharmacyte Biotech, (PMCB) mick 12/12/17 05:07:39 PM
#79113   good afternoon/ $PMCB mick 12/12/17 05:07:23 PM
#79112   I hope you’re right! As a matter of PINKribbon 12/12/17 12:19:33 PM
#79111   I like the experience they have, Maybe their PINKribbon 12/12/17 12:11:10 PM
#79110   Kano...after I read the testimonials on Practical Clinical efood125 12/12/17 11:48:41 AM
#79109   :) Christmas Blessings The Promised Land 12/12/17 08:28:32 AM
#79108   I believe a CRO has already been chosen BioInvestor4 12/12/17 06:34:54 AM
#79107   $PMCB PharmaCyte Biotech Meets with Oncology Advisory Bo $Pistol Pete$ 12/12/17 02:13:03 AM
#79106   Agreed Pink....we will never know...good post. efood125 12/11/17 11:01:40 PM
#79105   I agree Kano...sounds good PINKribbon 12/11/17 09:55:52 PM
#79104   I believe in one way or another von PINKribbon 12/11/17 09:51:14 PM
#79103   Thanks for that response doubt they have efood125 12/11/17 09:13:07 PM
#79102   After reading about Practical Clinical on their website, Kano58 12/11/17 09:08:36 PM
#79101   Could be because it will be cheaper in Kano58 12/11/17 08:41:02 PM
#79100   Hey Pink...I am interested in knowing what lead efood125 12/11/17 07:47:39 PM
#79099   I also agree Ciab thenewmixer 12/11/17 07:42:52 PM
#79098   Yes, I agree. However, I'm not as concerned PINKribbon 12/11/17 06:46:39 PM
#79097   It is already spell out on the table $Pistol Pete$ 12/11/17 03:27:12 PM
#79095   So Shady Kenny can't disclose to shareholders all concordia 12/11/17 02:53:02 PM
#79094   Pharmacyte Biotech, (PMCB) mick 12/11/17 12:13:25 PM
#79093   $PMCB awesome news today $Pistol Pete$ 12/11/17 12:06:42 PM
#79092   I like the fact we are hearing from A2Z 12/11/17 11:44:45 AM
#79091   Cheers, Go Trump Go PMCB rayla1961 12/11/17 11:38:44 AM
#79089   Go PMCB!!! The Promised Land 12/11/17 11:16:32 AM
#79087   volume looks good. i think we will tulla236a 12/11/17 10:50:55 AM
#79086   Current Report Filing (8-k) "Edgar (US Regulatory)" - mick 12/11/17 10:08:38 AM
#79085   Notice of Effectiveness (effect) "Edgar (US Regulatory)" - mick 12/11/17 10:08:32 AM
#79084   Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) "Edgar mick 12/11/17 10:07:53 AM
#79083   Securities Registration Statement (simplified Form) (s-3) "Edgar (US mick 12/11/17 10:07:34 AM
#79082   Quarterly Report (10-q) "Edgar (US Regulatory)" - 9/13/2017 mick 12/11/17 10:07:15 AM
#79081   Current Report Filing (8-k) "Edgar (US Regulatory)" - mick 12/11/17 10:06:57 AM
#79080   Annual Report (10-k) "Edgar (US Regulatory)" - 7/27/2017 mick 12/11/17 10:06:39 AM
#79079   PharmaCyte Biotech Appoints Dr. Linda S. Sher as mick 12/11/17 10:06:21 AM
#79078   PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to mick 12/11/17 10:06:01 AM
#79077   Pharmacyte Biotech, (PMCB) mick 12/11/17 10:01:55 AM
#79076   I’d say that there may have been CRO PINKribbon 12/11/17 09:59:46 AM
#79075   imo, i'd say these are the trial sites. tulla236a 12/11/17 09:34:20 AM
#79073   And the "HYPE" PR's begin. How many PR's concordia 12/11/17 09:28:13 AM
#79072   New PR. No big deal but shows some progress. rcstock 12/11/17 09:19:26 AM
#79071 BioInvestor4 12/11/17 09:15:29 AM
#79070   I too am confident. Schedule is the only concern. rcstock 12/11/17 08:20:37 AM
#79069   I for one am confident about the future BioInvestor4 12/11/17 08:05:17 AM
#79067 Kano58 12/11/17 12:42:50 AM
#79065   $PMCB Daily and Weekly Charts http://www.stock $Pistol Pete$ 12/10/17 01:52:01 PM